Abstract
The in vitro antifungal activities of the macrolide lactone antibiotic complex primycin (PC) and its main components, A1 (50%), A2 (7.3%) and C1 (13%), against the opportunistic pathogenic fungus Candida albicans 33erg+were determined by microdilution testing. The MIC100 (the minimal concentration required for 100% growth inhibition) values found, A2 (2 μg ml−1), PC (32 μg ml−1), A1 (32 μg ml−1) and C1 (64 μg ml−1), suggested that the biological activity of PC is highly dependent on the proportions of its constituents. In vivo measurements of the biophysical properties of plasma membranes were carried out by electron paramagnetic resonance (EPR) spectroscopic methods, using the spin probe 5-(4,4-dimethyloxazolidine-N-oxyl)stearic acid. Conventional EPR measurements demonstrated altered phase transition temperatures (Tm) of the plasma membrane of strain 33erg+ as a consequence of treatment with PC or its constituents: for cells treated with 128 μg ml−1 PC, A1, A2 or C1 for 15 min, Tm was 17, 21, 14.5 and 15 °C, respectively; that is significantly higher than the Tm of untreated cells, 12 °C. The molecular motions of the near-surface hydrophobic region of the plasma membrane, estimated by saturation transfer EPR spectroscopy, reflected changes in the membrane phases after the treatment. Two physiological membrane phases were detected in control samples: liquid-ordered and liquid-disordered, characterized by molecular movements ∼10−6–10−8 s and ⩾10−9 s. The cells treated with the investigated compounds showed the strong presence of a non-physiological gel phase additional to the above phases, characterized by movements ⩽10−5 s.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Tortorano, A. M. et al. Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents 27, 359–366 (2006).
Berman, J. & Sudbery, P. E. Candida albicans: a molecular revolution built on lessons from budding yeast. Nat. Rev. Gen. 3, 918–930 (2002).
Klepser, M. E. Candida resistance and its clinical relevance. Pharmacotherapy 26, 68–75 (2006).
Nógrádi, M. Primycin (Ebrimycin)–A new topical antibiotic. Drugs Today 24, 563–566 (1988).
Uri, J. V. & Actor, P. Crystallization and antifungal activity of primycin. J. Antibiot. 32, 1207–1209 (1979).
Uri, J. V. Antibacterial activity of primycin against multiple strains of Gram-positive bacteria. Acta Microbiol. Hung. 33, 141–146 (1986).
Blaskó, K. & Györgyi, S. Alkali ion transport of primycin modified erythrocytes. Acta Biol. Med. Germ. 40, 465–469 (1981).
Bálint, G. Favorable observations with Ebrimycin gel in the outpatient department of surgery. Ther. Hung. 35, 140–142 (1987).
Mészáros, C. & Vezekényi, K. Use of Ebrimycin gel in dermatology. Ther. Hung. 35, 77–79 (1987).
Papp, T., Ménesi, L. & Szalai, I. Experiences in the Ebrimycin gel treatment of burns. Ther. Hung. 38, 125–128 (1990).
Nyilasi, I. et al. In vitro interactions between primycin and different statins in their effects against some clinically important fungi. J. Med. Microbiol. 59, 200–205 (2010).
Virág, E., Belagyi, J., Gazdag, Z., Vágvölgyi, C. & Pesti, M. Direct in vivo interaction of the antibiotic primycin with the plasma membrane of Candida albicans: an EPR study. Biochim. Biophys. Acta (1818) 42-48, 2012.
Virág, E., Pesti, M. & Kunsági-Máté, S. Competitive hydrogen bonds associated with the effect of primycin antibiotic on oleic acid as a building block of plasma membranes. J. Antibiot. 63, 113–117 (2010).
Virág, E., Pesti, M. & Kunsági-Máté, S. Complex formation between primycin and ergosterol. Entropy-driven initiation of modification of the fungal plasma membrane structure. J. Antibiot. 65, 193–196 (2012).
Virág, E. et al. In vivo interaction of the antibiotic primycin on a Candida albicans clinical isolate and its ergosterol-less mutant. Acta Biol. Hung. 63, 42–55 (2012).
Szilágyi, I., Dékány, G., Frank, J., Horváth, G. & Kulcsár, G. Oxipricin, a new antibiotic. United States Patent num 4,873,348 (1989).
Prasad, R. Candida albicans. Cellular and molecular biology (Springer-Verlag: Heidelberg, 1991).
NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard. National Committee for Clinical Laboratory Standards. Document M27-A (NCCLS: Wayne, PA, 1997).
Horváth, L. I. & Marsh, D. Analysis of multicomponent saturation transfer ESR spectra using the integral method: application to membrane systems. J. Magn. Reson. 54, 363–373 (1983).
Goldman, S. A., Bruno, G. V. & Freed, J. H. Estimating slow motional rotational correlation times for nitroxides by electron spin resonance. J. Phys. Chem. 76, 1858–1860 (1972).
Knowles, P. F., Marsh, D. & Rattle, H. W. E. Magnetic resonance of biomolecules (Wiley Interscience, 1976).
Pesti, M., Gazdag, Z. & Belágyi, J. In vivo interaction of trivalent chromium with yeast plasma membrane, as revealed by EPR spectroscopy. FEMS Microbiol. Lett. 182, 375–380 (2000).
Eamann, M. & Deleu, M. From biological membranes to biomimetic model membranes. Biotechnol. Agron. Soc. Environ. 14, 719–736 (2010).
Squire, T. C. & Thomas, D. D. Methodology for increased precision in saturation transfer electron paramagnetic resonance studies of rotational dynamics. Biophys. J 49, 921–929 (1986).
Hemminga, M. A., Van der Dries, I. J., Magusin, P. C. M. M., Van Dusschoten, D. & Van der Berg, C. In Water management in the design and distribution of quality foods (eds, Roos Y. H., Leslie R. B., & Lillford P. J. ) (Technomic Publishing: Lancaster, 1999).
Wisniewska, A., Draus, J. & Subczynsky, W. K. Is a fluid mosaic model of biological membranes fully relevant? Studies on lipid organization in model and biological membranes. Lett. Cell. Molec. Biol. 8, 147–159 (2003).
Acknowledgements
This research was supported by grants RET-08/2005 and INNO-08-DA-PRIMYCIN and by PannonPharma Ltd., Pécsvárad, Hungary.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Virág, E., Belagyi, J., Kocsubé, S. et al. Antifungal activity of the primycin complex and its main components A1, A2 and C1 on a Candida albicans clinical isolate, and their effects on the dynamic plasma membrane changes. J Antibiot 66, 67–72 (2013). https://doi.org/10.1038/ja.2012.103
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2012.103
